📌 What is the AML Translocation Panel Test?
A molecular genetic test that detects specific chromosomal translocations associated with Acute Myeloid Leukemia (AML). These genetic changes help classify AML subtypes and guide treatment decisions.
📊 Normal Result
✔ Negative – No abnormal translocations detected (suggests no AML-associated genetic mutations)
🚨 Abnormal (Positive) Result May Indicate:
🔺 Presence of genetic translocations linked to AML, such as:
t(8;21) (RUNX1-RUNX1T1) → Associated with better prognosis
inv(16) or t(16;16) (CBFB-MYH11) → Common in core-binding factor AML
t(15;17) (PML-RARA) → Found in Acute Promyelocytic Leukemia (APL)
11q23/KMT2A (MLL) rearrangements → Poorer prognosis
FLT3-ITD, NPM1, CEBPA mutations (often tested alongside)
🎯 Purpose of the Test
✅ Diagnoses specific subtypes of AML
✅ Guides treatment choices (e.g., ATRA therapy for APL)
✅ Helps determine prognosis and risk stratification
✅ Monitors disease progression and response to therapy
💡 Key Facts
🔹 AML is a fast-growing blood cancer that affects white blood cells
🔹 Certain translocations indicate better or worse treatment outcomes
🔹 FISH, PCR, or NGS techniques are used to detect these genetic changes
🔹 Early detection improves targeted treatment options